Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma

Completed · Phase 2

Conditions studied: Kidney Cancer, Melanoma (Skin), Metastatic Cancer

In brief

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with brain metastases caused by kidney cancer or melanoma.

Key facts

Study ID

NCT00462982

Run by

Memorial Sloan Kettering Cancer Center

People needed

8

Starts

2007-03-01

Expected to finish

2008-08-01

Last updated by the study team

2015-12-30

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.